Focus: Axsome is a CNS-focused biotech company with a commercial portfolio centered on neurology treatments, anchored by AUVELITY for major depressive disorder. The company is actively scaling its commercial operations while advancing a pipeline of CNS programs.
Profile data last refreshed 10h ago · AI intelligence enriched 1mo ago
Growing — net +13 jobs in 30d
48 jobs added vs 35 removed. Steady team buildout.
Best suited for commercial and sales professionals seeking stability with growth; risky for scientists seeking R&D depth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Axsome Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Axsome Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Company's revenue anchor at 67% of total; NDA-approved with 17-year exclusivity runway provides long-term cash flow.
Second revenue pillar supporting commercial infrastructure; similar exclusivity window to AUVELITY.
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 Stocktwits
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages MarketBeat
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - fool.com
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? fool.com
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Yahoo Finance
AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280 - webull.com
AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280 webull.com
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM) The Globe and Mail
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Healthcare utilization and costs associated with dextromethorphan-bupropion versus selected other branded treatments for major depressive disorder: a US real-world study.
Real-World Switch Rates, Treatment Patterns, and Healthcare Costs Among Patients With Spasticity Treated With Botulinum Toxins.
+2 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo